SU533323A3 - Способ усилени биологической активности -окситриптофана - Google Patents
Способ усилени биологической активности -окситриптофанаInfo
- Publication number
- SU533323A3 SU533323A3 SU1940152A SU1940152A SU533323A3 SU 533323 A3 SU533323 A3 SU 533323A3 SU 1940152 A SU1940152 A SU 1940152A SU 1940152 A SU1940152 A SU 1940152A SU 533323 A3 SU533323 A3 SU 533323A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- hydroxytryptophan
- hydrazine
- trioxybenzyl
- seryl
- biological activity
- Prior art date
Links
- 230000004071 biological effect Effects 0.000 title description 4
- 230000002708 enhancing effect Effects 0.000 title description 2
- 238000000034 method Methods 0.000 title description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229960002888 oxitriptan Drugs 0.000 description 12
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 11
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- -1 D, L-seryl Chemical group 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- LDCYZAJDBXYCGN-UHFFFAOYSA-N 5-hydroxytryptophan Chemical compound C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002072 seryl group Chemical group 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH984672 | 1972-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU533323A3 true SU533323A3 (ru) | 1976-10-25 |
Family
ID=4356299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU1940152A SU533323A3 (ru) | 1972-06-30 | 1973-06-28 | Способ усилени биологической активности -окситриптофана |
Country Status (18)
| Country | Link |
|---|---|
| AT (1) | AT338412B (enExample) |
| AU (1) | AU476456B2 (enExample) |
| BE (1) | BE801645A (enExample) |
| CA (1) | CA1015272A (enExample) |
| DD (1) | DD107592A5 (enExample) |
| DE (1) | DE2327636A1 (enExample) |
| ES (1) | ES416383A1 (enExample) |
| FR (1) | FR2190453B1 (enExample) |
| GB (1) | GB1369189A (enExample) |
| HU (1) | HU167292B (enExample) |
| IE (1) | IE37833B1 (enExample) |
| IL (1) | IL42317A (enExample) |
| LU (1) | LU67898A1 (enExample) |
| NL (1) | NL7308435A (enExample) |
| PH (1) | PH9584A (enExample) |
| SE (1) | SE407744B (enExample) |
| SU (1) | SU533323A3 (enExample) |
| ZA (1) | ZA733284B (enExample) |
-
1973
- 1973-05-15 ZA ZA733284A patent/ZA733284B/xx unknown
- 1973-05-18 AU AU55897/73A patent/AU476456B2/en not_active Expired
- 1973-05-21 IL IL42317A patent/IL42317A/en unknown
- 1973-05-30 DE DE19732327636 patent/DE2327636A1/de active Pending
- 1973-06-18 NL NL7308435A patent/NL7308435A/xx not_active Application Discontinuation
- 1973-06-22 IE IE1034/72A patent/IE37833B1/xx unknown
- 1973-06-27 FR FR7323456A patent/FR2190453B1/fr not_active Expired
- 1973-06-28 ES ES416383A patent/ES416383A1/es not_active Expired
- 1973-06-28 PH PH14782*UA patent/PH9584A/en unknown
- 1973-06-28 SU SU1940152A patent/SU533323A3/ru active
- 1973-06-28 LU LU67898A patent/LU67898A1/xx unknown
- 1973-06-28 CA CA175,140A patent/CA1015272A/en not_active Expired
- 1973-06-29 HU HUHO1588A patent/HU167292B/hu unknown
- 1973-06-29 BE BE132885A patent/BE801645A/xx unknown
- 1973-06-29 GB GB3107173A patent/GB1369189A/en not_active Expired
- 1973-06-29 DD DD171943A patent/DD107592A5/xx unknown
- 1973-06-29 AT AT574273A patent/AT338412B/de not_active IP Right Cessation
- 1973-06-29 SE SE7309254A patent/SE407744B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU167292B (enExample) | 1975-09-27 |
| AU476456B2 (en) | 1976-09-23 |
| SE407744B (sv) | 1979-04-23 |
| LU67898A1 (enExample) | 1975-04-11 |
| PH9584A (en) | 1976-01-19 |
| IE37833B1 (en) | 1977-10-26 |
| ATA574273A (de) | 1976-12-15 |
| DD107592A5 (enExample) | 1974-08-12 |
| AU5589773A (en) | 1974-11-21 |
| IE37833L (en) | 1973-12-30 |
| IL42317A (en) | 1976-04-30 |
| IL42317A0 (en) | 1973-07-30 |
| DE2327636A1 (de) | 1974-01-17 |
| FR2190453A1 (enExample) | 1974-02-01 |
| GB1369189A (en) | 1974-10-02 |
| BE801645A (fr) | 1974-01-02 |
| AT338412B (de) | 1977-08-25 |
| FR2190453B1 (enExample) | 1976-04-09 |
| CA1015272A (en) | 1977-08-09 |
| NL7308435A (enExample) | 1974-01-02 |
| ZA733284B (en) | 1974-03-27 |
| ES416383A1 (es) | 1976-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2892753A (en) | Central nervous system stimulant | |
| KR950009094B1 (ko) | 과유지질혈증 및 아테롬성 동맥경화증의 방지 및 치료용 피리독신 유도체를 함유한 제약학적 조성물 | |
| EA015382B1 (ru) | Применение рофлумиласта для лечения сахарного диабета типа 2 | |
| US4898729A (en) | Treatment of hypertension, compounds and compositions for antihypertension and diuresis | |
| JPS6313967B2 (enExample) | ||
| US3557292A (en) | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine | |
| RU92004569A (ru) | Фармацевтический препарат антистрессорного, стресспротекторного и ноотропного действия | |
| DE3875611T2 (de) | Pharmazeutische zusammensetzungen. | |
| SU533323A3 (ru) | Способ усилени биологической активности -окситриптофана | |
| US3896232A (en) | Substituted benzylidene hydrazines as anti-migraine syndrome agents | |
| RU2084225C1 (ru) | Гипотензивное средство | |
| RU2283114C1 (ru) | Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы | |
| RU2725622C1 (ru) | Фармацевтическая композиция для лечения и/или профилактики заболеваний печени | |
| RU2152221C1 (ru) | Средство, обладающее гепатопротекторным, холестерино- и сахарорегулирующим действием | |
| US3932652A (en) | Antidepressant compositions | |
| Borysiewicz et al. | Scombrotoxic atrial flutter | |
| US3360434A (en) | Method for reducing blood pressure with phenylalanine derivatives | |
| IE71022B1 (en) | Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamides containing preparation and stabilizing method therefor | |
| DE69301360T2 (de) | Neuroprotektivum | |
| RU2225713C1 (ru) | Фармацевтическая композиция, обладающая антиангинальным, антиишемическим и ноотропным действием | |
| RU2341254C1 (ru) | Стабильная фармацевтическая композиция, обладающая антигипертензивным действием | |
| RU2019184C1 (ru) | Способ получения биологически активного средства на основе березового сока | |
| US4218466A (en) | Method of treating gastric and duodenal ulcers | |
| IE60601B1 (en) | Therapeutic agent for the treatment of disorders associated with cerebral ischemia | |
| US10647745B2 (en) | Compound for treating sequelae of ischemic cerebral stroke |